Kura Oncology

Kura Oncology is a clinical stage biopharmaceutical company advancing a pipeline of precision medicines for the treatment of solid tumors and blood cancers. The Company's lead product candidate, tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. Tipifarnib is a new chemical entity, or NCE, and a member of a class of product candidates called farnesyl transferase inhibitors, or FTIs. Protein farnesylation is a key cell signaling process implicated in various cancer processes, including survival, growth and proliferation of tumor cells. 

Company Growth (employees)
Type
Public
HQ
San Diego, US
Founded
2007
Size (employees)
30 (est)+12%
Kura Oncology was founded in 2007 and is headquartered in San Diego, US

Kura Oncology Office Locations

Kura Oncology has an office in San Diego
San Diego, US (HQ)
125 11119 N Torrey Pines Rd

Kura Oncology Financials and Metrics

Kura Oncology Financials

USD

Net income (Q3, 2017)

(9.3 m)

Market capitalization (13-Nov-2017)

388.3 m
Kura Oncology's current market capitalization is $388.3 m.
USDFY, 2016

Net Income

(27.6 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

R&D expense

3.3 m3 k3.6 m4 m4.3 m5.2 m5.2 m

General and administrative expense

1.5 m63 k2.4 m1.8 m1.7 m2.1 m2.2 m

Operating expense total

5.9 m66 k7 m6.8 m7.1 m7.7 m7.9 m9.5 m

Interest expense

42 k42 k42 k189 k194 k203 k209 k226 k
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

6.6 k5.6 k15.4 m9.7 m

Accounts Receivable

92.4 m

Inventories

693 k725 k

Current Assets

86.9 m68.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Inventories

909 k

Accounts Payable

6.2 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (28.6 k)(30.7 k)(3.7 m)(27.6 m)

    Depreciation and Amortization

    1 k31 k

    Inventories

    (42 k)(32 k)

    Accounts Payable

    (1.5 k)2.1 k833 k471 k
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

    Net Income

    (5.6 m)(66 k)(6.6 m)(6.7 m)(6.9 m)(7.5 m)(9.3 m)

    Inventories

    909 k

    Accounts Payable

    6507138.2 k10.7 k2.5 m3.7 m3.1 m3.3 m4.2 m3.7 m4.2 m6.2 m
      Show all financial metrics

      Kura Oncology Operating Metrics

      FY, 2016

      Phase II Trials

      1

      Phase Preclinical

      2
      Show all operating metrics

      Kura Oncology Market Value History

      Kura Oncology's Web-traffic and Trends

      Kura Oncology Company Life and Culture

      You may also be interested in